Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
1999-9-20
pubmed:abstractText
Pharmacological reperfusion therapy for acute myocardial infarction with intravenous fibrinolytic agents improves survival yet fails to achieve early and complete coronary blood flow in nearly half of treated patients. In principle, glycoprotein (GP) IIb/IIIa inhibitors, potent antiplatelet agents, might improve the efficacy and clinical outcomes associated with fibrinolysis. Preclinical research suggests more rapid and effective reperfusion with combined platelet GP IIb/IIIa inhibition and fibrinolysis. Early clinical studies confirm improved early patency and more rapid electrocardiographic resolution, but increased bleeding complications, with the addition of GP IIb/IIIa antagonists to conventional fibrinolysis. Future studies may combine reduced-dose fibrinolytic therapy with GP IIb/IIIa inhibition to optimize efficacy and safety.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
http://linkedlifedata.com/resource/pubmed/chemical/Acetates, http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal, http://linkedlifedata.com/resource/pubmed/chemical/Fibrinogen, http://linkedlifedata.com/resource/pubmed/chemical/Fibrinolytic Agents, http://linkedlifedata.com/resource/pubmed/chemical/Immunoglobulin Fab Fragments, http://linkedlifedata.com/resource/pubmed/chemical/Peptides, http://linkedlifedata.com/resource/pubmed/chemical/Plasminogen Activators, http://linkedlifedata.com/resource/pubmed/chemical/Platelet Aggregation Inhibitors, http://linkedlifedata.com/resource/pubmed/chemical/Platelet Glycoprotein GPIIb-IIIa..., http://linkedlifedata.com/resource/pubmed/chemical/Tyrosine, http://linkedlifedata.com/resource/pubmed/chemical/abciximab, http://linkedlifedata.com/resource/pubmed/chemical/eptifibatide, http://linkedlifedata.com/resource/pubmed/chemical/lamifiban
pubmed:status
MEDLINE
pubmed:month
Jun
pubmed:issn
0929-5305
pubmed:author
pubmed:issnType
Print
pubmed:volume
7
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
241-5
pubmed:dateRevised
2007-11-15
pubmed:meshHeading
pubmed-meshheading:10373717-Acetates, pubmed-meshheading:10373717-Animals, pubmed-meshheading:10373717-Antibodies, Monoclonal, pubmed-meshheading:10373717-Clinical Trials, Phase II as Topic, pubmed-meshheading:10373717-Clinical Trials as Topic, pubmed-meshheading:10373717-Dogs, pubmed-meshheading:10373717-Double-Blind Method, pubmed-meshheading:10373717-Drug Evaluation, Preclinical, pubmed-meshheading:10373717-Drug Therapy, Combination, pubmed-meshheading:10373717-Fibrinogen, pubmed-meshheading:10373717-Fibrinolytic Agents, pubmed-meshheading:10373717-Forecasting, pubmed-meshheading:10373717-Humans, pubmed-meshheading:10373717-Immunoglobulin Fab Fragments, pubmed-meshheading:10373717-Myocardial Infarction, pubmed-meshheading:10373717-Peptides, pubmed-meshheading:10373717-Pilot Projects, pubmed-meshheading:10373717-Plasminogen Activators, pubmed-meshheading:10373717-Platelet Aggregation Inhibitors, pubmed-meshheading:10373717-Platelet Glycoprotein GPIIb-IIIa Complex, pubmed-meshheading:10373717-Randomized Controlled Trials as Topic, pubmed-meshheading:10373717-Recurrence, pubmed-meshheading:10373717-Treatment Outcome, pubmed-meshheading:10373717-Tyrosine
pubmed:year
1999
pubmed:articleTitle
Use of glycoprotein IIb/IIIa inhibition plus fibrinolysis in acute myocardial infarction.
pubmed:affiliation
Duke University Medical Center, Duke Clinical Research Institute, Durham, North Carolina 27715, USA.
pubmed:publicationType
Journal Article, Review